Quanterix (QTRX) Expected to Announce Quarterly Earnings on Tuesday

Quanterix (NASDAQ:QTRX - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $28.27 million for the quarter. Quanterix has set its FY 2025 guidance at EPS.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). The business had revenue of $35.16 million during the quarter, compared to analysts' expectations of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quanterix Price Performance

Shares of NASDAQ:QTRX traded up $0.24 during midday trading on Friday, reaching $6.01. 477,565 shares of the company's stock were exchanged, compared to its average volume of 553,056. The firm's 50 day simple moving average is $6.35 and its two-hundred day simple moving average is $9.32. Quanterix has a fifty-two week low of $4.67 and a fifty-two week high of $19.18. The stock has a market cap of $233.12 million, a price-to-earnings ratio of -5.67 and a beta of 1.12.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Leerink Partners reiterated a "market perform" rating and issued a $8.00 target price (down previously from $12.00) on shares of Quanterix in a report on Wednesday. Leerink Partnrs downgraded Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Canaccord Genuity Group reduced their price target on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Finally, Scotiabank restated an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Quanterix has an average rating of "Moderate Buy" and a consensus target price of $16.20.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.